ABUS - Arbutus Biopharma Corp
IEX Last Trade
3.185
0.025 0.785%
Share volume: 18,755
Last Updated: Fri 27 Dec 2024 06:30:03 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
0.40%
PREVIOUS CLOSE
CHG
CHG%
$3.16
0.03
0.79%
Fundamental analysis
25%
Profitability
25%
Dept financing
7%
Liquidity
75%
Performance
18%
Performance
5 Days
-0.31%
1 Month
-6.74%
3 Months
-19.70%
6 Months
5.65%
1 Year
33.05%
2 Year
36.48%
Key data
Stock price
$3.18
DAY RANGE
$3.12 - $3.20
52 WEEK RANGE
$2.27 - $4.72
52 WEEK CHANGE
$25.20
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/07/2024
Company detail
CEO: William H. Collier
Region: US
Website: arbutusbio.com
Employees: 90
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: arbutusbio.com
Employees: 90
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Arbutus Biopharma Corporation develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate. AB-836, an oral capsid inhibitor that suppresses HBV DNA replication, is in Phase Ia/Ib clinical trial targeted to hepatocytes.
Recent news